683 Capital Management, LLC Adverum Biotechnologies, Inc. Transaction History

683 Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $102,581 - $1.03 Million	-106,856 Reduced 51.66%	100,000 $95,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $86,553 - $143,187	106,856 Added 106.86%	206,856 $248,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $174,000 - $240,000	-100,000 Reduced 50.0%	100,000 $176,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $416,000 - $720,000	200,000 New	200,000 $434,000
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $1.88 Million - $5.7 Million	-358,986 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $17,340 - $40,426	-3,400 Reduced 0.94%	358,986 $4.27 Million
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $958,126 - $1.98 Million	333,842 Added 1169.57%	362,386 $1.14 Million
Q3 2018 Nov 14, 2018	BUY	$4.5 - $7.6 $128,448 - $216,934	28,544 New	28,544 $173,000
Q1 2018 May 15, 2018	SELL	$3.65 - $7.95 $2.01 Million - $4.37 Million	-550,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.65 $735,000 - $1.1 Million	300,000 Added 120.0%	550,000 $2.01 Million
Q4 2016 Dec 07, 2017	BUY	N/A	250,000	250,000 $725,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.